IP Library Granted Patent US 10,710,999
Granted Patent B2
US 10,710,999 · App. 16/338,832 · Granted Jul 14, 2020

Polymorph of an intermediate for palbociclib synthesis

Inventors: Mahdeshkumar Gadakar (Hyderabad, IN); Dnyandeo Punde (Hyderabad, IN); Rajendra Yadav (Hyderabad, IN); Yogesh Wakchaure (Hyderabad, IN)
Assignee: MYLAN LABORATORIES LIMITED
C07D471/04C07B2200/13
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,710,999
App. No.
16/338,832
Granted
Jul 14, 2020
Kind
B2
Abstract

The present disclosure provides a novel polymorph of an intermediate useful in the preparation of palbociclib. The polymorph has enhanced properties that influence process ability of the intermediate and synthesis of palbociclib.

Claims (13)

1. Crystalline Form M of a compound of Formula-2

characterized by a powder X-ray diffraction pattern having peaks at 6.0 and 8.7±0.2°2θ.

2. The crystalline Form M of Formula-2 as in claim 1 further characterized by a powder X-ray diffraction pattern having peaks at 6.0, 6.3, 8.7, 12.0, 15.3, 19.1, and 22.6±0.2°2θ.

3. The crystalline Form M of Formula-2 as in claim 1 , further characterized by the powder X-ray diffraction pattern of in FIG. 1 .

4. A process for the preparation of crystalline Form M of Formula-2, as in claim 1 , comprising the steps of:

a) dissolving a compound of Formula-2 in a solvent selected from the group consisting of alcohols, tetrahydrofuran, and mixtures thereof to form a reaction mixture;

b) heating the reaction mixture;

c) optionally adding a seed of Form M of Formula-2;

d) slowly cooling the reaction mixture; and

3 ) isolating crystalline Form M of Formula-2.

5. The process of claim 4 , wherein the alcohol is selected from the group consisting of methanol, ethanol, isopropanol, and mixtures thereof.

6. The process of claim 4 , wherein the reaction mixture is heated to 110° C. in the heating step and wherein the reaction mixture is cooled to 15° C. in the cooling step.

7. Crystalline Form M of Formula-2 prepared according to the process pf claim 4 , further having a purity of 99.0%.

Assignments (3)
CHANGE OF NAME Recorded Jan 12, 2026
From: TIANISH LABORATORIES PRIVATE LIMITED
To: MATRIX PHARMACORP PRIVATE LIMITED
Reel/Frame 074322/0525 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 6, 2024
From: MYLAN LABORATORIES LIMITED
To: TIANISH LABORATORIES PRIVATE LIMITED
Reel/Frame 068861/0150 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 8, 2020
From: WAKCHAURE, YOGESH; YADAV, RAJENDRA; GADAKAR, MAHESHKUMAR; PUNDE, DNYANDEO
To: MYLAN LABORATORIES LIMITED
Reel/Frame 052862/0857 →
Priority Claims (1)
IN 201641034492 · Oct 7, 2016 · national
Continuity (1)
Related Publication 20190225608A1 · Jul 25, 2019